Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

Conclusion Further evaluation of PLD, bortezomib, and deacetylase inhibitor combinations is warranted, with special attention directed toward strategies to improve tolerability. Micro-Abstract We evaluated the combination of pegylated liposomal doxorubicin, bortezomib and vorinostat in 32 patients with relapsed/refractory multiple myeloma in a phase I study. The maximum tolerated dose of vorinostat with PLD/bortezomib was 400 mg on days 4 to 11. Clinical activity was seen including in bortezomib-refractory patients. However, hematologic, constitutional and gastrointestinal toxicity was common.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research